Retatrutide bụ peptide sịntetik ọhụrụ emebere ka ọ rụọ ọrụ n'otu oge ndị na-anabata isi atọ na-etinye aka na glucose homeostasis na nguzozi ike: glucagon receptor (GCGR), glucose-based insulinotropic polypeptide receptor (GIPR) na glucagon-dị ka peptide-1 nnabata (GLP- 1R) (Finan et al., 2023, The New England Journal of Medicine).Site n'ilekwasị anya na ndị na-anabata ndị a, retatrutide na-eṅomi mmetụta nke ligands ha dị iche iche, glucagon, GIP na GLP-1, bụ hormones na-achịkwa glucose metabolism na arọ ahụ na anụ ahụ dị iche iche, dị ka pancreas, imeju, ụbụrụ, adipose anụ ahụ na eriri afọ. traktị (Drucker, 2023, Nature).
N'adịghị ka ligands endogenous, nke nwere obere ọkara ndụ, mmebi ngwa ngwa site na dipeptidyl peptidase-4 (DPP-4) enzyme na mmetụta ndị na-adịghị mma, dị ka hypoglycemia na ọgbụgbọ (Drucker, 2023, Nature), emeziwo retatrutide iji merie ndị a. oke.Retatrutide bụ ngwakọta peptide mejupụtara usoro glucagon gbanwetụrụ jikọtara ya na usoro GLP-1 gbanwere site na usoro GIP (Finan et al., 2023, The New England Journal of Medicine).Mgbanwe ndị a gụnyere ngbanwe amino acid na mkpochapụ na-eme ka nkwụsi ike, ike na nhọrọ nke peptide atọ maka ndị nnata atọ (Finan et al., 2023, The New England Journal of Medicine).
Retatrutide egosila akụrụngwa ọgwụ dị ịrịba ama na nrụpụta ọgwụgwọ na oke ibu na ụdị ọrịa shuga 2 na nyocha izizi na ụlọ ọgwụ.N'ụdị anụmanụ nke oke ibu na ọrịa shuga, retatrutide egosila mmetụta dị elu na iweda ọkwa glucose ọbara, na-akpali akpali nzuzo insulin, na-egbochi glucagon secretion, na-egbu oge ịgbasa gastric, ibelata oriri na ịdị arọ ahụ ma e jiri ya tụnyere otu ma ọ bụ abụọ agonists nke ndị na-anabata atọ (Gault et al. al., 2023, Ọrịa shuga, oke ibu na metabolism; Coskun et al., 2023a, Molecular Metabolism).Retatrutide emewokwa ka profaịlụ lipid dịkwuo mma, ọrụ imeju, mbufụt na usoro obi na anụmanụ ndị a (Gault et al., 2023, Diabetes, Obesity and Metabolism; Coskun et al., 2023a, Molecular Metabolism).
N'ime ule ụlọ ọgwụ mmadụ, retatrutide egosiwokwa nsonaazụ na-ekwe nkwa na ndị ọrịa buru ibu na ndị ọrịa mamịrị.A nabatara Retatrutide nke ọma ma gosipụta mmetụta na-adabere na dose na iwetulata ọkwa glucose ọbara, na-akpali mmepụta insulin, na-egbochi secretion glucagon na ibelata agụụ na ọmụmụ nke 1 nke metụtara ndị ọrụ afọ ofufo ahụike na ndị ọrịa nwere ụdị ọrịa shuga 2 (Coskun et al., 2023b, Diabetes Care) ).Retatrutide nwetara ihe ruru 17.5% pụtara mbelata ịdị arọ na izu 24 ma e jiri ya tụnyere placebo na nyocha nke abụọ nke metụtara ndị ọrịa nwere oke ibu na oke ibu.Mbelata ibu a sochiri ya na mmụba na njikwa glycemic, profaịlụ lipid, ọrụ imeju na ịdị mma nke ndụ (Nsonaazụ Lilly's phase 2 retatrutide nke e bipụtara na New England Journal of Medicine na-egosi molecule nyocha enwetara ihe ruru 17.5% pụtara mbelata ibu na izu 24 n'ime. ndị okenye nwere oke ibu na oke ibu., 2023).Retatrutide nwekwara profaịlụ nchekwa dị mma na-enweghị ihe ọ bụla dị njọ ma ọ bụ ọnọdụ hypoglycemia kọrọ.
Ọgụgụ 1. Retatrutide (LY3437943) na-egbochi glycated hemoglobin A1c (HbA1c) uru (A) na bodyweight (B) ka oge na-aga.
(Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, akwụkwọ akụkọ atọ GIP, GLP-1, na glucagon agonist receptor agonist na ndị nwere ụdị ọrịa shuga 2: usoro 1b, multicentre, okpukpu abụọ kpuru, ebe a na-achịkwa placebo, randomized, nnwale dose na-arịgo ọtụtụ. Lancet.
Retatrutide nọ ugbu a na mmepe site na Eli Lilly na Company dị ka onye nyocha ọgwụ ọhụrụ maka oke ibu na ụdị ọrịa shuga 2.Ọ na-anọchi anya ụzọ ọhụụ iji lekwasịrị anya ọtụtụ ndị na-anabata ihe na-etinye aka na metabolism glucose na nguzozi ike na otu molekul.Retatrutide egosila nrụpụta dị ịrịba ama na ụdị anụmanụ na nnwale mmadụ nwere ezigbo nchekwa na profaịlụ nnabata.Ọmụmụ ihe ndị ọzọ dị mkpa iji kwado uru ya na-adịte aka na ihe ize ndụ ndị nwere ike ime na ọnụ ọgụgụ buru ibu ma dị iche iche.Retatrutide nwere ike ịnye nhọrọ ọhụrụ maka ndị ọrịa na-alụ ọgụ na oke ibu na ọrịa shuga ma chọọ ọgwụgwọ dị irè karị.
Anyị bụ ndị na-emepụta polypeptide na China, nwere ahụmahụ tozuru okè na mmepụta polypeptide ọtụtụ afọ.Hangzhou Taijia Biotech Co., Ltd bụ ọkachamara polypeptide akụrụngwa emeputa, nke nwere ike inye iri puku kwuru iri puku polypeptide akụrụngwa na nwekwara ike ahaziri dị ka mkpa.Ogo nke ngwaahịa polypeptide dị mma, ịdị ọcha nwere ike iru 98%, nke ndị ọrụ ghọtara n'ụwa niile. Nnọọ ịkpọtụrụ anyị.
